Published • loading... • Updated
Rational Design and Efficacy Evaluation of a Novel Solid Dispersion-Based Bempedoic Acid–Ezetimibe Fixed-Dose Combination Tablet Versus Nexlizet®
Summary by Pharma Excipients
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Rational Design and Efficacy Evaluation of a Novel Solid Dispersion-Based Bempedoic Acid–Ezetimibe Fixed-Dose Combination Tablet Versus Nexlizet®
Abstract Background/Objectives: For hyperlipidemic patients with statin resistance, a fixed-dose combination of a non-statin drug such as ezetimibe (EZT) and bempedoic acid (BA) provides a significant benefit. Although both drugs exhibit poor aqueous solubility, the oral bioavailability of EZT is more critically limited by dissolution, whereas BA maintains adequate absorption due to its high intestinal permeability. With regard to the reference …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
